Head of COPD

AstraZeneca - Gaithersburg, MD (30+ days ago)4.1

At AstraZeneca we believe in the potential of our people and we’ll develop you beyond what you thought possible. We make the most of your skills and passion by actively supporting you to see what you can achieve no matter where you start with us.

Global Portfolio and Product Strategy (GPPS) is the strategic unit that shapes AstraZeneca’s product and portfolio strategy. We integrate corporate, product and therapy area strategies in order to provide clear strategic direction that bridges our science and commercial teams, while maximising the value of our portfolio and brands.

This role sits within the Respiratory Therapy Area Group whose remit is to develop long-term strategies across all therapy area assets to maximise growth.
Leading product strategies from science units (i.e. Development) through to commercialisation and lifecycle management.
Shape portfolio and product strategies, providing strategic direction and commercial management.
Supplement portfolio and capabilities through business development opportunities.

Benralizumab (FASENRA®) is the only humanized, afucosylated, immunoglobulin G1k (IgG1k) isotype monoclonal antibody that directly binds to the human interleukin 5 receptor alpha (hIL-5Rα) on eosinophils and basophils. Benralizumab is uniquely engineered to recruit natural killer cells directly to its target, resulting in active apoptosis via antibody-dependent cellular cytotoxicity (ADCC).
The targeted mechanism of action of Benralizumab induces direct and near complete depletion of eosinophils in the airways, lung, sputum, blood, and bone marrow. Depletion of eosinophils is rapid and durable, with blood eosinophils completely depleted (0 cells/μL) 24 hours following subcutaneous dosing with benralizumab and which remain depleted during treatment with doses given every 8 weeks.
Fasenra is currently indicated as an add on treatment to standard of care for patients with eosinophilic Severe Uncontrolled Asthma with approval granted in US, EU, Japan and Canada at February 2018. Future indications are part of the clinical development plan and include COPD, Nasal Polyps (currently in Ph3) and other eosinophilic non-airways diseases such as EGPA, HES and EoE (currently being assessed)

Fasenra is the first launched respiratory biologic for AstraZeneca and represents one of the top company priorities within the respiratory TA and the overall portfolio.

Within the Respiratory Global Portfolio and Product Strategy (GPPS) team and reporting to the commercial VP, Fasenra, you will be the strategy and launch lead for the COPD indication.

You will be accountable for the development and implementation of the commercial strategy and compelling promotional plans for this indication, up to and including, promotional communication materials, global campaign, global promotional activities, launch preparation workshop, sales support materials etc... according to the brand strategy. You will represent the commercial voice in the GDT (Global Development Team) providing input and contributing to the decision making on future clinical development projects

The successful individual will demonstrate strong skills in the areas of strategic thinking, decision making, communication, leadership, problem solving and collaboration.

Main Duties And Responsibilities:
As the global Marketing Director Fasenra COPD you will represent GPPS and be accountable for:
Leading the COPD commercial strategy definition
Represent the commercial COPD voice within the global cross functional product team
Lead the global COPD commercial working group and GBT
Engaging with the local head of marketing to ensure a flawless and aligned execution of the strategy
Engaging with KEEs to gather input to inform the COPD strategy and activities plan including advocacy development

Education: Business degree is required with science expertise as preferred

Significant experience in healthcare or biopharma industry, with a strong preference for experience in the respiratory therapeutic area and biologic drugs.
In-depth understanding of commercial strategy, methodologies and tools (product profiling and positioning, forecasting, pricing & reimbursement, market research techniques, competitive intelligence resources)
Thorough ‘hands-on’ knowledge of building TPPs, generating sales forecasts and business cases.
Experience of shaping brand strategy whilst the understanding of product profile was incomplete and evolving
Thorough understanding of the drug development process and the need for commercial line of sight throughout
Understanding of future healthcare market challenges including local regulatory DO’s and DON’Ts
Exposure to and track record of effective management of senior decision-making/governance bodies
Proven experience of engaging with and leveraging insights from external customers e.g. KEEs, prescribers, payors

Special Skills/Abilities:
Strong strategic thinking, decision making, and problem solving
Strong leadership and influencing skills to ensure a strong commercial focus in R&D projects
Proven ability to collaborate across functional boundaries
Demonstrated ability to bring ideas to action
Strong analytical, organizational and communication skills (written and verbal) required

AstraZeneca is an equal opportunity employer. AstraZeneca will consider all qualified applicants for employment without discrimination on grounds of disability, sex or sexual orientation, pregnancy or maternity leave status, race or national or ethnic origin, age, religion or belief, gender identity or re-assignment, marital or civil partnership status, protected veteran status (if applicable) or any other characteristic protected by law. AstraZeneca only employs individuals with the right to work in the country/ies where the role is advertised.